As previously reported on Tuesday, Wells Fargo upgraded Clorox (CLX) to Equal Weight from Underweight with a price target of $157, up from $155. While the firm says it continues to struggle with Clorox’s sustainable sales growth profile, namely as the benefits of easier comps are now over and sales growth has reverted to negative again, it also acknowledges some key relative positives for Clorox, namely more EPS visibility. That make an Underweight rating unreasonable, Wells adds.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLX:
- Clorox upgraded to Equal Weight from Underweight at Wells Fargo
- Clorox price target raised to $164 from $161 at Deutsche Bank
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
